Frier Levitt attorneys presented an essential update on recent developments in tirzepatide compounding. With the FDA reconsidering its block on compounding Lilly’s obesity drug, a recent court ruling has permitted 503B facilities to resume compounding tirzepatide. This shift introduces uncertainty within the 503A pharmacy compounding space but may also open new opportunities for healthcare professionals and patients relying on this medication.
Our attorneys unpacked the ruling, its implications for tirzepatide compounding and dispensing, and the potential impact on the future landscape.
Key Topics:
- The impact of the judge’s decision on 503A and 503B compounding, purchasing, and dispensing tirzepatide.
- Key details about the legal case challenging the FDA’s decisions.
- What the future might hold for the availability of tirzepatide.
- Risk mitigation for 503A compounders.
- What compounders need to know now.
Why Watch? This webinar offers healthcare professionals an essential opportunity to understand the legal issues surrounding tirzepatide. Our speakers will break down the complexities of the case, explain its significance, and clarify how these changes could impact your practice.
Target Audience: This webinar is ideal for pharmacy professionals, including pharmacy owners, pharmacists, and pharmacy technicians.
